Skip to main content
Premium Trial:

Request an Annual Quote

Zycos Wins DNA-Delivery Patent

NEW YORK, Nov. 19 — Zycos, a Lexington, Mass., drug-development company, announced on Monday that it has been granted a patent on its microparticle DNA delivery method.

 

According to the company, the invention, called GENCAP, protects DNA from degradation in the body. The microparticles that protect the DNA are derived from a material also used in resorbable sutures, and Zycos has adapted the material to encapsulate and protect plasmid DNA vaccines.

 

This technique, according to the company, is superior to naked DNA vaccines in its ability to deliver antigen-coding DNA into relevant immune system cells and generate a robust B-cell and cytotoxic T-cell response.

 

The patent was granted on Oct. 30.

 

Zycos is also developing its own drug pipeline, focusing on treatments for cancers, infectious diseases and autoimmune disorders, and currently has one treatment for cervical dysplasia in early clinical trials.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.